Search company, investor...

Erox

Founded Year

1989

Stage

IPO | IPO

Total Raised

$5.8M

Date of IPO

1/6/1993

About Erox

Developer of fragrances containing human pheromones for use in perfumes and cosmetic products. Pheromones are biochemical products known to play a vital role in the mating process of various species of animals. In humans, pheromones affect the hypothalamus, the part of the brain that assists in regulating appetite, anger, sex drive, and temperature. The company believes that pheromones affect the brain and nervous system through small cavities inside the nasal passages.

Headquarters Location

Fremont, California, 94536,

United States

(510)226-6874

Missing: Erox's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Erox's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Erox Frequently Asked Questions (FAQ)

  • When was Erox founded?

    Erox was founded in 1989.

  • Where is Erox's headquarters?

    Erox's headquarters is located at Fremont.

  • What is Erox's latest funding round?

    Erox's latest funding round is IPO.

  • How much did Erox raise?

    Erox raised a total of $5.8M.

  • Who are the investors of Erox?

    Investors of Erox include Deucalion, Technology Funding and MK Global Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.